recombinant human ace-2 protein, cf Search Results


recombinant human ace2  (R&D Systems)
94
R&D Systems recombinant human ace2
Serum <t>ACE2</t> activity is significantly correlated with SBP in stroke-alert patients and healthy young adults, but not AIS patients. Correlation graphs of ACE2 activity and SBP among stroke-alert patients (a) and healthy young adults (b) as compared to stroke patients (c). Young adult blood plasma samples in panel (b) were from a biorepository established by Wegman et al., which were obtained from research participants undergoing baseline measurements. (d) Correlation graph of ACE activity and mRS at discharge from hospital among AIS patients. ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; mRS: modified Rankin score; RFU: relative fluorescence unit; SBP: systolic blood pressure.
Recombinant Human Ace2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+ace-2+protein%2C+cf/Recombinant+Human+ACE-2+Protein%2C+CF/pmc05843889-88-10-13
Average 94 stars, based on 1 article reviews
recombinant human ace2 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
recombinant human ace 2 fc chimera  (R&D Systems)
92
R&D Systems recombinant human ace 2 fc chimera
Serum <t>ACE2</t> activity is significantly correlated with SBP in stroke-alert patients and healthy young adults, but not AIS patients. Correlation graphs of ACE2 activity and SBP among stroke-alert patients (a) and healthy young adults (b) as compared to stroke patients (c). Young adult blood plasma samples in panel (b) were from a biorepository established by Wegman et al., which were obtained from research participants undergoing baseline measurements. (d) Correlation graph of ACE activity and mRS at discharge from hospital among AIS patients. ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; mRS: modified Rankin score; RFU: relative fluorescence unit; SBP: systolic blood pressure.
Recombinant Human Ace 2 Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+ace-2+protein%2C+cf/Recombinant+Human+ACE-2+Fc+Chimera+Protein%2C+CF/pmc08986157-50-4-10
Average 92 stars, based on 1 article reviews
recombinant human ace 2 fc chimera - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
biotinylated recombinant human ace2  (R&D Systems)
90
R&D Systems biotinylated recombinant human ace2
Inhibitory effects of different polyphenols on the interaction between SARS-CoV-2 spike protein receptor binding domain (RBD (N501Y)) and human angiotensin-converting enzyme 2 <t>(ACE2).</t> ( A ) 10 µM of pelargonidin-3-O-glucoside (Pel-3-O-G), malvidin-3-O-glucoside (Mal-3-O-G), cyanidin-3-O-glucoside (Cya-3-O-G), peonidin, tannic acid (TA), 1,3,6-tri-O-galloyl-β-D-glucose (TGG), and corilagin were tested to evaluate their ability to inhibit the binding of immobilized spike protein (0.5 µg/mL) to human, biotin-labeled ACE2 (0.25 µg/mL) by using an enzyme-linked immunosorbent assay (ELISA). Dose effect inhibition of 0.1, 1, and 5 µM ( B ) TA, ( C ) TGG, and ( D ) corilagin. The absorbance of ACE2 (0.25 µg/mL) at 450 nm was set to 100%. Results are expressed as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test with * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ACE2 (0.25 µg/mL).
Biotinylated Recombinant Human Ace2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+ace-2+protein%2C+cf/Recombinant+Human+ACE-2+Fc+Chimera+Biotinylated+Protein%2C+CF/pmc08910432-205-0-15
Average 90 stars, based on 1 article reviews
biotinylated recombinant human ace2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
bt933  (R&D Systems)
94
R&D Systems bt933
Inhibitory effects of different polyphenols on the interaction between SARS-CoV-2 spike protein receptor binding domain (RBD (N501Y)) and human angiotensin-converting enzyme 2 <t>(ACE2).</t> ( A ) 10 µM of pelargonidin-3-O-glucoside (Pel-3-O-G), malvidin-3-O-glucoside (Mal-3-O-G), cyanidin-3-O-glucoside (Cya-3-O-G), peonidin, tannic acid (TA), 1,3,6-tri-O-galloyl-β-D-glucose (TGG), and corilagin were tested to evaluate their ability to inhibit the binding of immobilized spike protein (0.5 µg/mL) to human, biotin-labeled ACE2 (0.25 µg/mL) by using an enzyme-linked immunosorbent assay (ELISA). Dose effect inhibition of 0.1, 1, and 5 µM ( B ) TA, ( C ) TGG, and ( D ) corilagin. The absorbance of ACE2 (0.25 µg/mL) at 450 nm was set to 100%. Results are expressed as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test with * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ACE2 (0.25 µg/mL).
Bt933, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+ace-2+protein%2C+cf/Recombinant+Human+ACE-2+His-tag+Biotinylated+Protein%2C+CF/pmc08455247-335-12-9
Average 94 stars, based on 1 article reviews
bt933 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
recombinant human ace 2 his tag biotinylated protein  (R&D Systems)
91
R&D Systems recombinant human ace 2 his tag biotinylated protein
Inhibitory effects of different polyphenols on the interaction between SARS-CoV-2 spike protein receptor binding domain (RBD (N501Y)) and human angiotensin-converting enzyme 2 <t>(ACE2).</t> ( A ) 10 µM of pelargonidin-3-O-glucoside (Pel-3-O-G), malvidin-3-O-glucoside (Mal-3-O-G), cyanidin-3-O-glucoside (Cya-3-O-G), peonidin, tannic acid (TA), 1,3,6-tri-O-galloyl-β-D-glucose (TGG), and corilagin were tested to evaluate their ability to inhibit the binding of immobilized spike protein (0.5 µg/mL) to human, biotin-labeled ACE2 (0.25 µg/mL) by using an enzyme-linked immunosorbent assay (ELISA). Dose effect inhibition of 0.1, 1, and 5 µM ( B ) TA, ( C ) TGG, and ( D ) corilagin. The absorbance of ACE2 (0.25 µg/mL) at 450 nm was set to 100%. Results are expressed as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test with * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ACE2 (0.25 µg/mL).
Recombinant Human Ace 2 His Tag Biotinylated Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+ace-2+protein%2C+cf/Recombinant+Human+ACE-2+His-tag+Biotinylated+Protein%2C+CF/pm41937394-44-0-7
Average 91 stars, based on 1 article reviews
recombinant human ace 2 his tag biotinylated protein - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
recombinant human ace-2 fc chimera avi-tag protein (cho), cf  (R&D Systems)
N/A
Recombinant Human ACE-2 Fc Chimera Avi-tag Protein (CHO), CF
   Buy from Supplier
recombinant human ace 2 protein cf  (R&D Systems)
N/A
The Recombinant Human ACE 2 Protein from R D Systems is derived from NS0 The Recombinant Human ACE 2 Protein has been validated for the following applications Enzyme Activity
   Buy from Supplier
recombinant human ace-2 his-tag avi-tag protein (cho), cf  (R&D Systems)
N/A
Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO), CF
   Buy from Supplier

Image Search Results


Serum ACE2 activity is significantly correlated with SBP in stroke-alert patients and healthy young adults, but not AIS patients. Correlation graphs of ACE2 activity and SBP among stroke-alert patients (a) and healthy young adults (b) as compared to stroke patients (c). Young adult blood plasma samples in panel (b) were from a biorepository established by Wegman et al., which were obtained from research participants undergoing baseline measurements. (d) Correlation graph of ACE activity and mRS at discharge from hospital among AIS patients. ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; mRS: modified Rankin score; RFU: relative fluorescence unit; SBP: systolic blood pressure.

Journal: Journal of the Renin-Angiotensin-Aldosterone System: JRAAS

Article Title: Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke

doi: 10.1177/1470320316661060

Figure Lengend Snippet: Serum ACE2 activity is significantly correlated with SBP in stroke-alert patients and healthy young adults, but not AIS patients. Correlation graphs of ACE2 activity and SBP among stroke-alert patients (a) and healthy young adults (b) as compared to stroke patients (c). Young adult blood plasma samples in panel (b) were from a biorepository established by Wegman et al., which were obtained from research participants undergoing baseline measurements. (d) Correlation graph of ACE activity and mRS at discharge from hospital among AIS patients. ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; mRS: modified Rankin score; RFU: relative fluorescence unit; SBP: systolic blood pressure.

Article Snippet: Reaction Km and Vmax were determined using control samples and recombinant human ACE2 (R&D Systems, Inc., #933-ZN-010) as a positive control, and all samples were run in duplicate.

Techniques: Activity Assay, Clinical Proteomics, Modification, Fluorescence

Activity of ACE2 and ACE in serum is altered following stroke. For human serum, bar graphs are means ± SEM and represent enzyme activity levels of ACE2 (a) and ACE (c) from control, stroke-alert, or AIS patients at an average of 3.6 hours and again at 3 days after stroke. Individual differences and means ± SEM in ACE2 (b) and ACE (d) are shown. * P <0.05 versus control and † P <0.05 versus stroke-alert. ‡ P <0.05 versus AIS <6 hours. ACE: angiotensin converting enzyme; ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; RFU: relative fluorescence unit.

Journal: Journal of the Renin-Angiotensin-Aldosterone System: JRAAS

Article Title: Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke

doi: 10.1177/1470320316661060

Figure Lengend Snippet: Activity of ACE2 and ACE in serum is altered following stroke. For human serum, bar graphs are means ± SEM and represent enzyme activity levels of ACE2 (a) and ACE (c) from control, stroke-alert, or AIS patients at an average of 3.6 hours and again at 3 days after stroke. Individual differences and means ± SEM in ACE2 (b) and ACE (d) are shown. * P <0.05 versus control and † P <0.05 versus stroke-alert. ‡ P <0.05 versus AIS <6 hours. ACE: angiotensin converting enzyme; ACE2: angiotensin converting enzyme 2; AIS: acute ischemic stroke; RFU: relative fluorescence unit.

Article Snippet: Reaction Km and Vmax were determined using control samples and recombinant human ACE2 (R&D Systems, Inc., #933-ZN-010) as a positive control, and all samples were run in duplicate.

Techniques: Activity Assay, Control, Fluorescence

Predictors of acute ischemic stroke by multiple linear regression analysis.

Journal: Journal of the Renin-Angiotensin-Aldosterone System: JRAAS

Article Title: Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke

doi: 10.1177/1470320316661060

Figure Lengend Snippet: Predictors of acute ischemic stroke by multiple linear regression analysis.

Article Snippet: Reaction Km and Vmax were determined using control samples and recombinant human ACE2 (R&D Systems, Inc., #933-ZN-010) as a positive control, and all samples were run in duplicate.

Techniques: Activity Assay

Inhibitory effects of different polyphenols on the interaction between SARS-CoV-2 spike protein receptor binding domain (RBD (N501Y)) and human angiotensin-converting enzyme 2 (ACE2). ( A ) 10 µM of pelargonidin-3-O-glucoside (Pel-3-O-G), malvidin-3-O-glucoside (Mal-3-O-G), cyanidin-3-O-glucoside (Cya-3-O-G), peonidin, tannic acid (TA), 1,3,6-tri-O-galloyl-β-D-glucose (TGG), and corilagin were tested to evaluate their ability to inhibit the binding of immobilized spike protein (0.5 µg/mL) to human, biotin-labeled ACE2 (0.25 µg/mL) by using an enzyme-linked immunosorbent assay (ELISA). Dose effect inhibition of 0.1, 1, and 5 µM ( B ) TA, ( C ) TGG, and ( D ) corilagin. The absorbance of ACE2 (0.25 µg/mL) at 450 nm was set to 100%. Results are expressed as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test with * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ACE2 (0.25 µg/mL).

Journal: International Journal of Molecular Sciences

Article Title: Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity

doi: 10.3390/ijms23052643

Figure Lengend Snippet: Inhibitory effects of different polyphenols on the interaction between SARS-CoV-2 spike protein receptor binding domain (RBD (N501Y)) and human angiotensin-converting enzyme 2 (ACE2). ( A ) 10 µM of pelargonidin-3-O-glucoside (Pel-3-O-G), malvidin-3-O-glucoside (Mal-3-O-G), cyanidin-3-O-glucoside (Cya-3-O-G), peonidin, tannic acid (TA), 1,3,6-tri-O-galloyl-β-D-glucose (TGG), and corilagin were tested to evaluate their ability to inhibit the binding of immobilized spike protein (0.5 µg/mL) to human, biotin-labeled ACE2 (0.25 µg/mL) by using an enzyme-linked immunosorbent assay (ELISA). Dose effect inhibition of 0.1, 1, and 5 µM ( B ) TA, ( C ) TGG, and ( D ) corilagin. The absorbance of ACE2 (0.25 µg/mL) at 450 nm was set to 100%. Results are expressed as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test with * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ACE2 (0.25 µg/mL).

Article Snippet: Biotinylated recombinant human ACE2 with purity >95% and camostat mesylate compound were both purchased from R&D Systems (Minneapolis, MN, USA).

Techniques: Binding Assay, Labeling, Enzyme-linked Immunosorbent Assay, Inhibition